Shanghai Kaibao Pharmaceutical CO.,Ltd

300039

CNE100000JZ3

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 03/07/2024 am IST			5-day change	1st Jan Change
5.38 ^CNY	-0.92%		-1.10%	-19.10%

13/06	Shanghai Kaibao Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for Year 2023, Payable on June 19, 2024	CI
06/06	Shanghai Kaibao Pharmaceutical Co.,Ltd Approves the By-Election of Wang Guoming as Non-Independent Director	CI

Shanghai Kaibao Pharmaceutical Co.,Ltd Approves the Cash Dividend for the Year 2023

June 07, 2024 at 01:02 am IST

Shanghai Kaibao Pharmaceutical CO.,Ltd held its Annual General Meeting of 2023 on 05 June 2024, approved the Cash dividend/10 shares (tax included) of CNY 1.00000000 for the year 2023.

Latest news about Shanghai Kaibao Pharmaceutical CO.,Ltd

Shanghai Kaibao Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for Year 2023, Payable on June 19, 2024	14/06	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Approves the By-Election of Wang Guoming as Non-Independent Director	07/06	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Approves the Cash Dividend for the Year 2023	07/06	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Proposes Final Dividend for the Year 2023	27/04	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	25/04	CI
Maling Aquarius' President Resigns	06/03	MT
Shanghai Kaibao Pharmaceutical CO.,Ltd Announces Executive Changes	26/12	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	17/23/17	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	08/23/08	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd. Approves Cash Dividend for 2022, Payable on 26 May 2023	16/23/16	CI
Shanghai Maling Aquarius Names Chairman	11/23/11	MT
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	24/23/24	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Announces the Profit Distribution Proposal for 2022	20/23/20	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	18/23/18	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd(XSEC:300039) added to S&P Global BMI Index	19/22/19	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	15/22/15	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Announces Final Cash Dividend on A Shares for 2021, Payable on 16 June 2022	09/22/09	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Approves Cash Dividend for the Year 2021	21/22/21	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Proposes Cash Dividend for 2021	27/22/27	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI
Shanghai Kaibao Pharmaceutical CO.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	27/21/27	CI
Shanghai Kaibao Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	25/21/25	CI

Chart Shanghai Kaibao Pharmaceutical CO.,Ltd

Duration

Period

Chart Shanghai Kaibao Pharmaceutical CO.,Ltd

More charts

Shanghai Kaibao Pharmaceutical CO.,Ltd. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent drugs. The Company's main product is Tanreqing injection, which is used for treatment of upper respiratory tract infections, such as cold and pneumonia. The Company's products include injections, tablets, capsules, granules, vinum and pills, among others. The Company distributes its products in domestic markets.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI KAIBAO PHARMACEUTICAL CO.,LTD	-19.10%	774M
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+38.59%	621B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+13.40%	238B
ROCHE HOLDING AG	+0.61%	221B
NOVARTIS AG	+13.24%	218B
AMGEN INC.	+7.42%	166B

Other Pharmaceuticals